AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36091012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg, subcutaneous, every 4 weeks)
Number of subjects: 0
Study 36091012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34698726 — intervention group
Group type: EXPERIMENTAL
Intervention: Short antibiotic prophylaxis (24 hours)
Number of subjects: 85
Study 34698726 — intervention group
Group type: COMPARATOR
Intervention: Extended antibiotic prophylaxis (7 days)
Number of subjects: 85
Study 32024741 — intervention group
Group type: COMPARATOR
Intervention: Education in Amharic
Number of subjects: 84
Study 32024741 — intervention group
Group type: EXPERIMENTAL
Intervention: Education in English
Number of subjects: 84
Study 32024741 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Amharic and English)
Number of subjects: 84
Study 36330836 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery cognitive bias modification (imagery CBM)
Number of subjects: 188
Study 36330836 — intervention group
Group type: COMPARATOR
Intervention: Control arm (four weeks of weekly questionnaires)
Number of subjects: 188
Study 34391232 — intervention group
Group type: EXPERIMENTAL
Intervention: GT100Hz
Number of subjects: 280
Study 34391232 — intervention group
Group type: EXPERIMENTAL
Intervention: GT2Hz
Number of subjects: 280
Study 34391232 — intervention group
Group type: EXPERIMENTAL
Intervention: GI4KHz/100Hz
Number of subjects: 280
Study 34391232 — intervention group
Group type: EXPERIMENTAL
Intervention: GI2KHz/100Hz
Number of subjects: 280
Study 34391232 — intervention group
Group type: EXPERIMENTAL
Intervention: GI4KHz/2Hz
Number of subjects: 280
Study 34391232 — intervention group
Group type: EXPERIMENTAL
Intervention: GI2KHz/2Hz
Number of subjects: 280
Study 34391232 — intervention group
Group type: COMPARATOR
Intervention: GIP (placebo interferential group)
Number of subjects: 280
Study 34391232 — intervention group
Group type: COMPARATOR
Intervention: GTP (placebo TENS group)
Number of subjects: 280
Study 32384147 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine therapy (100 mg/kg IV 3 times/day)
Number of subjects: 12
Study 32384147 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine therapy (loading dose 200 mg/kg then 100 mg/kg TID)
Number of subjects: 12
Study 32384147 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine therapy (loading dose 200 mg/kg followed by continuous infusion 300 mg/kg per day)
Number of subjects: 12
Study 32384147 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine therapy (all doses)
Number of subjects: 12
Study 32384147 — intervention group
Group type: COMPARATOR
Intervention: Control group (steady-state cohort)
Number of subjects: 12
Study 35997833 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte‐poor platelet‐rich plasma (LP‐PRP) + hyaluronic acid (HA)
Number of subjects: 50
Study 35997833 — intervention group
Group type: COMPARATOR
Intervention: Autologous microfragmented adipose tissue (AMAT)
Number of subjects: 50
Study 34797272 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based cognitive behavioral therapy (Y-CBT)
Number of subjects: 58
Study 34797272 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 58
Study 33283717 — intervention group
Group type: EXPERIMENTAL
Intervention: AML group (patients with acute myeloid leukemia)
Number of subjects: 30
Study 36369984 — intervention group
Group type: EXPERIMENTAL
Intervention: Bursectomy
Number of subjects: 1204
Study 36369984 — intervention group
Group type: COMPARATOR
Intervention: Omentectomy alone
Number of subjects: 1204
Study 33164936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 800 IU/day
Number of subjects: 183
Study 33164936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching starch granules)
Number of subjects: 183
Study 35537465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (BrAC = .10%)
Number of subjects: 94
Study 35537465 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 94
Study 34474163 — intervention group
Group type: EXPERIMENTAL
Intervention: Elafin
Number of subjects: 526
Study 34474163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ST2 and REG3α
Number of subjects: 526
Study 34474163 — intervention group
Group type: EXPERIMENTAL
Intervention: Elafin combined with ST2 and REG3α
Number of subjects: 526
Study 35698203 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) group - loading dose of 1 μg/kg for 15 min and continuous infusion at 0.6 μg/kg/h until 30 min before the end of operation.
Number of subjects: 120
Study 35698203 — intervention group
Group type: COMPARATOR
Intervention: Control group - normal saline infusion.
Number of subjects: 120
Study 33256794 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope™ visualization
Number of subjects: 86
Study 33256794 — intervention group
Group type: COMPARATOR
Intervention: Neck flexion with lateral neck pressure
Number of subjects: 86
Study 34030163 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 25)
Number of subjects: 50
Study 34030163 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study 33676504 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening decision aid (DA) prototype
Number of subjects: 27
Study 35162346 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL of plain 0.5% ropivacaine with perineurally added 1 mL/4 mg of dexamethasone (Group I)
Number of subjects: 45
Study 35162346 — intervention group
Group type: COMPARATOR
Intervention: 4 mL of plain 0.5% ropivacaine with perineurally added 1 mL of 0.9% saline (Group II)
Number of subjects: 45
Study 35162346 — intervention group
Group type: COMPARATOR
Intervention: 4 mL of plain 0.5% bupivacaine with perineurally added 1 mL of 0.9% saline (Group III)
Number of subjects: 45
Study 33446115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) + 2 nucleos(t)ides (NRTIs)
Number of subjects: 707
Study 33446115 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 707
Study 32745830 — intervention group
Group type: EXPERIMENTAL
Intervention: mindfulness+values
Number of subjects: 206
Study 32745830 — intervention group
Group type: COMPARATOR
Intervention: values only
Number of subjects: 206
Study 35934082 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN1908/1909 600 mg
Number of subjects: 56
Study 35934082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 33933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Data completeness assessment
Number of subjects: 1839
Study 33933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Data accuracy assessment
Number of subjects: 1839
Study 33933340 — intervention group
Group type: EXPERIMENTAL
Intervention: Data verification
Number of subjects: 1839
Study 33933340 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 1839
Study 33588513 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional microphone with noise reduction on
Number of subjects: 19
Study 33588513 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional microphone with noise reduction off
Number of subjects: 19
Study 33588513 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnidirectional microphone with noise reduction on
Number of subjects: 19
Study 33588513 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnidirectional microphone with noise reduction off
Number of subjects: 19
Study 33588513 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory capacity (WMC) group
Number of subjects: 19
Study 33588513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerable time estimates
Number of subjects: 19
Study 34935603 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training along with conventional physical therapy (CPT)
Number of subjects: 18
Study 34935603 — intervention group
Group type: COMPARATOR
Intervention: FES for Rectus Abdominis and Erector Spinae with CPT
Number of subjects: 18
Study 34935603 — intervention group
Group type: COMPARATOR
Intervention: Control group (FES + CPT)
Number of subjects: 18
Study 33661437 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 989
Study 32455947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (12-week weight loss program)
Number of subjects: 137
Study 32455947 — intervention group
Group type: COMPARATOR
Intervention: Control group (Q1, no significant weight loss)
Number of subjects: 137
Study 36008108 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (50,000 IU bi-weekly)
Number of subjects: 113
Study 36008108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 34798706 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB-LSAL with 0.5% ropivacaine (25 mL)
Number of subjects: 106
Study 34798706 — intervention group
Group type: COMPARATOR
Intervention: TQLB with 0.5% ropivacaine (25 mL)
Number of subjects: 106
Study 34798706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 106
Study 36064382 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan supplementation
Number of subjects: 64
Study 36064382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 64
Study 34486986 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg/day
Number of subjects: 3245
Study 34486986 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg/day
Number of subjects: 3245
Study 34486986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3245
Study 34486986 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline (both dosages)
Number of subjects: 3245
Study 36651339 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐AES
Number of subjects: 302
Study 36651339 — intervention group
Group type: COMPARATOR
Intervention: PP‐ZES
Number of subjects: 302
Study 33831611 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 74
Study 33831611 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical treatment (MST)
Number of subjects: 74
Study 33831611 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 74
Study 32084522 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose spatially fractionated radiation therapy (12 to 14 Gy via dose cylinders)
Number of subjects: 25
Study 32084522 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (external beam radiation therapy to the entire prostate and proximal seminal vesicles to 76 Gy at 2 Gy/fraction)
Number of subjects: 25
Study 32571103 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisbane Evidence-Based Language Test
Number of subjects: 0
Study 34802471 — intervention group
Group type: COMPARATOR
Intervention: Brief BP counseling and an educational brochure
Number of subjects: 100
Study 34802471 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitor (HBPM) with a mailed report of their home readings
Number of subjects: 100
Study 34256607 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200 mg/day)
Number of subjects: 68
Study 34256607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 34460904 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic Stewardship Rounds (ASRs)
Number of subjects: 4683
Study 34460904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ASRs)
Number of subjects: 4683
Study 34033975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy (platinum and pemetrexed)
Number of subjects: 332
Study 34033975 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (platinum and pemetrexed)
Number of subjects: 332
Study 34033975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 332
Study 34033975 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 332
Study 35653758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing emotion labels before sorting (e.g., 'happy faces go here')
Number of subjects: 128
Study 35653758 — intervention group
Group type: COMPARATOR
Intervention: Not given labels (e.g., 'faces like this go here')
Number of subjects: 128
Study 35396587 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) and cetuximab (Cet)
Number of subjects: 218
Study 33536102 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10-20 mg/day)
Number of subjects: 100
Study 33536102 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (0.2 mg/kg/day)
Number of subjects: 100
Study 33536102 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (50 mg/kg/day)
Number of subjects: 100
Study 33536102 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 100
Study 32114933 — intervention group
Group type: EXPERIMENTAL
Intervention: WiiNWalk (experimental group)
Number of subjects: 64
Study 32114933 — intervention group
Group type: COMPARATOR
Intervention: Attention control (control group)
Number of subjects: 64
Study 35714357 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TEAS (group E1)
Number of subjects: 90
Study 35714357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative TEAS (group E2)
Number of subjects: 90
Study 35714357 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90
Study 32196462 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth positive psychology program intervention group
Number of subjects: 654
Study 32196462 — intervention group
Group type: COMPARATOR
Intervention: Relevant online mental health information control group
Number of subjects: 654
Study 35833600 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight self-awareness plan (WAP)
Number of subjects: 279
Study 33894422 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-quarter view stimuli
Number of subjects: 0
Study 33894422 — intervention group
Group type: COMPARATOR
Intervention: Front view stimuli
Number of subjects: 0
Study 32339664 — intervention group
Group type: EXPERIMENTAL
Intervention: verum-tDCS
Number of subjects: 24
Study 32339664 — intervention group
Group type: COMPARATOR
Intervention: sham-tDCS
Number of subjects: 24
Study 35037116 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (900 mg/day)
Number of subjects: 59
Study 35037116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 32321451 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 105
Study 32321451 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 33540038 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (a structured multicomponent exercise program comprised of aerobic and resistance training as well as impact loading)
Number of subjects: 115
Study 33540038 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 115
Study 33540038 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 115
Study 32746774 — intervention group
Group type: EXPERIMENTAL
Intervention: 200g of cod twice a week for 16 weeks
Number of subjects: 137
Study 32746774 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (control group)
Number of subjects: 137
Study 36416197 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted advertising on Facebook
Number of subjects: 282
Study 33880558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 1274
Study 33880558 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir/abacavir/lamivudine (DTG/ABC/3TC)
Number of subjects: 1274
Study 33880558 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir + emtricitabine/tenofovir alafenamide (DTG+F/TAF)
Number of subjects: 1274
Study 33253318 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (2x/week for 6 months)
Number of subjects: 65
Study 33253318 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 65
Study 33253318 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 65
Study 33253318 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline visceral-to-subcutaneous fat ratio (VFR)
Number of subjects: 65
Study 33253318 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of muscle mass
Number of subjects: 65
Study 35404227 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol administered orally 60 to 75 minutes prior to psychotherapeutic sessions
Number of subjects: 0
Study 34472211 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbial synthesis of the SCFA butyrate
Number of subjects: 482
Study 32748579 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (NMB) group
Number of subjects: 100
Study 32748579 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (NMB) group
Number of subjects: 100
Study 32748579 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Deep and Moderate NMB)
Number of subjects: 100
Study 34618513 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' self-perceived alliance-fostering effectiveness
Number of subjects: 212
Study 34618513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral orientation
Number of subjects: 212
Study 33831625 — intervention group
Group type: COMPARATOR
Intervention: Surgical dressing changed twice a week (HMO)
Number of subjects: 84
Study 33831625 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical dressing untouched until first follow up (SDU)
Number of subjects: 84
Study 33831625 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical dressing removed at first postoperative day (SDR)
Number of subjects: 84
Study 33264808 — intervention group
Group type: EXPERIMENTAL
Intervention: ReliaTect Post‐Op Dressing (RELIATECT)
Number of subjects: 160
Study 33264808 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing (STANDARD)
Number of subjects: 160
Study 32268807 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress testing
Number of subjects: 9210
Study 32268807 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomographic Angiography (CTA)
Number of subjects: 9210
Study 36343740 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0mg vitamin K1 I.M.
Number of subjects: 75
Study 36343740 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg vitamin K1 I.M.
Number of subjects: 75
Study 36343740 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3mg vitamin K1 I.M.
Number of subjects: 75
Study 33547573 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconference training
Number of subjects: 132
Study 33547573 — intervention group
Group type: COMPARATOR
Intervention: In-person workshop training
Number of subjects: 132
Study 33105353 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Alanine (12 g/d for 14 days)
Number of subjects: 19
Study 33105353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 34155637 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (8 sessions)
Number of subjects: 53
Study 34155637 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (8 sessions of behavior therapy after wait list)
Number of subjects: 53
Study 34196442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol (50 mg extended release)
Number of subjects: 21
Study 34196442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg extended release)
Number of subjects: 21
Study 34196442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 34953520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab 500 mg
Number of subjects: 546
Study 34953520 — intervention group
Group type: EXPERIMENTAL
Intervention: BRII-196 plus BRII-198 (1000 mg each)
Number of subjects: 546
Study 34953520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study 33137103 — intervention group
Group type: EXPERIMENTAL
Intervention: IMARA program
Number of subjects: 199
Study 33137103 — intervention group
Group type: COMPARATOR
Intervention: Health promotion control program
Number of subjects: 199
Study 33580345 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR + LET
Number of subjects: 20
Study 33580345 — intervention group
Group type: COMPARATOR
Intervention: ACLR
Number of subjects: 20
Study 33319566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum (GL) 6 g/day for 6 weeks
Number of subjects: 0
Study 33319566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceratonia siliqua (CS) 6 g/day for 6 weeks
Number of subjects: 0
Study 34644395 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment MRI showing 100% fibrotic fistula
Number of subjects: 50
Study 34644395 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment MRI MAGNIFI-CD index
Number of subjects: 50
Study 34644395 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of fibrosis at post-treatment MRI
Number of subjects: 50
Study 34644395 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGNIFI-CD index at post-treatment MRI
Number of subjects: 50
Study 34644395 — intervention group
Group type: EXPERIMENTAL
Intervention: Youden cut-off point for MAGNIFI-CD index
Number of subjects: 50
Study 32200813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monthly treatment
Number of subjects: 1107
Study 32200813 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab monthly treatment
Number of subjects: 1107
Study 32200813 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly treatment
Number of subjects: 1107
Study 32200813 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed treatment
Number of subjects: 1107
Study 32200813 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from monthly to as-needed treatment
Number of subjects: 1107
Study 32200813 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 1107
Study 32200813 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 1107
Study 33461181 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-focused atomic deposition (LFAD)
Number of subjects: 0
Study 33461181 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme ultraviolet (EUV) interference lithography
Number of subjects: 0